Drug Profile

INV 400

Alternative Names: INV-400

Latest Information Update: 30 Nov 2022

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator INVENT Pharmaceuticals
Class Antidepressants; Anxiolytics; Behavioural disorder therapies; Small molecules
Mechanism of Action G protein-coupled receptor modulators

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

Preclinical Anxiety disorders; Attention-deficit hyperactivity disorder; Depressive disorders

30 Nov 2022 Preclinical trials in Anxiety disorders in USA prior to 30 November 2022 (PO) (Invent Pharmaceuticals pipeline, November 2022)
30 Nov 2022 Preclinical trials in Attention-deficit hyperactivity disorder in USA prior to 30 November 2022 (PO) (Invent Pharmaceuticals pipeline, November 2022)
30 Nov 2022 Preclinical trials in Depressive disorders in USA prior to 30 November 2022 (PO) (Invent Pharmaceuticals pipeline, November 2022)

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com